5,900 Shares in Veeva Systems Inc. $VEEV Acquired by Westwind Capital

Key Points

• Westwind Capital acquired 5,900 Veeva Systems shares in the third quarter, valued at approximately $1.684 million. Institutional investors and hedge funds collectively own 88.2% of the company.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $284.88; several firms recently raised their targets to as high as $325.
• Veeva recently exceeded quarterly expectations, reporting $2.35 in EPS versus $2.23 expected and $927.96 million in revenue. Revenue increased 17.6% year over year, while shares recently traded at $284.78.

Westwind Capital acquired a new stake in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,900 shares of the technology company's stock, valued at approximately $1,684,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Fundsmith LLP acquired a new stake in shares of Veeva Systems in the second quarter worth $144,955,000. Arrowstreet Capital Limited Partnership boosted its position in Veeva Systems by 203.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 913,281 shares of the technology company's stock valued at $160,427,000 after purchasing an additional 611,868 shares during the last quarter. Swedbank AB grew its stake in Veeva Systems by 43.5% in the first quarter. Swedbank AB now owns 1,645,128 shares of the technology company's stock valued at $288,983,000 after purchasing an additional 498,971 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Veeva Systems by 43.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,593,795 shares of the technology company's stock worth $279,970,000 after purchasing an additional 483,720 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in shares of Veeva Systems by 757.5% during the 1st quarter. Pacer Advisors Inc. now owns 485,046 shares of the technology company's stock valued at $85,203,000 after buying an additional 428,478 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Barclays increased their price objective on Veeva Systems from $275.00 to $315.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. Jefferies Financial Group reiterated a "buy" rating and issued a $295.00 target price on shares of Veeva Systems in a research note on Thursday, August 27th. Guggenheim increased their price target on shares of Veeva Systems from $276.00 to $310.00 and gave the stock a "buy" rating in a research note on Thursday, August 27th. Stifel Nicolaus set a $300.00 price target on shares of Veeva Systems in a report on Thursday, August 27th. Finally, Royal Bank Of Canada lifted their price objective on shares of Veeva Systems from $275.00 to $325.00 and gave the company an "outperform" rating in a research note on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $284.88.

Veeva Systems Price Performance

Shares of NYSE VEEV traded up $2.28 during trading hours on Thursday, hitting $284.78. 921,680 shares of the company's stock were exchanged, compared to its average volume of 2,342,119. The company's 50-day moving average price is $259.17 and its 200-day moving average price is $202.93. Veeva Systems Inc. has a 1-year low of $148.05 and a 1-year high of $303.39. The stock has a market capitalization of $46.11 billion, a price-to-earnings ratio of 46.84, a PEG ratio of 1.21 and a beta of 0.93.

Veeva Systems (NYSE:VEEV - Get Free Report) last released its earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.23 by $0.12. The firm had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The company's revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, research analysts expect that Veeva Systems Inc. will post 6.7 earnings per share for the current year.

Insider Buying and Selling at Veeva Systems

In other news, EVP Daniel J. Rizzo sold 4,841 shares of the company's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $276.51, for a total transaction of $1,338,584.91. Following the completion of the transaction, the executive vice president owned 7,665 shares of the company's stock, valued at approximately $2,119,449.15. This represents a 38.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Priscilla Hung sold 750 shares of Veeva Systems stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total value of $195,780.00. Following the sale, the director directly owned 3,242 shares in the company, valued at approximately $846,291.68. This trade represents a 18.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 51,591 shares of company stock valued at $13,355,945 in the last ninety days. Company insiders own 10.60% of the company's stock.

Key Headlines Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva Basics adoption is expanding. More than 175 emerging biotechs are using the preconfigured platform across clinical, regulatory, quality, medical, and commercial operations. The announcement supports Veeva’s ability to win customers early and expand them as they advance toward commercialization. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical-data automation is showing meaningful scale. Veeva says its Development Quality Solution has cleaned data for more than 1 million clinical-trial subjects across over 1,000 studies, highlighting customer usage and the potential for automation to improve retention and cross-selling. Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
• Positive Sentiment: Management is highlighting continued platform momentum. CEO Peter Gassner said nearly 200 customers are using Veeva Basics, while the upcoming R&D and Quality Summit will showcase AI tools and customer use cases involving Eli Lilly, Pfizer, Sanofi, UCB, and others. The event may reinforce Veeva’s positioning as an important software provider for modern drug development. Veeva Summit to Showcase AI Innovations
• Positive Sentiment: Technical momentum remains strong. Market commentary says VEEV is nearing several buy points as institutional money returns to software companies with sticky enterprise customers. Veeva’s entrenched position in pharma data and workflows is viewed as a potential AI-era advantage. Software Leader Veeva Systems Positioned To Hit Buy Points After Nearly Doubling

Veeva Systems Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company's product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.